PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) (“Day One”) on behalf of the company’s investors.
Since February 2023, shares of Day One’s common stock have declined in value from a trading price of over $20.00 per share to a current trading price of less than $11.50 per share, a cumulative decline of over 42% in value.
The investigation seeks to determine whether the company’s officers and/or directors breached their fiduciary duties or violated the securities laws in connection with recent corporate actions.
Day One stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/day-one/ , for additional information about this investigation and their legal rights and options.
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com
This notice may constitute attorney advertising in certain jurisdictions.
- DoubleVerify Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 21, 2025 to Discuss Your Rights – DV - July 3, 2025
- McEwen Mining Announces:Voting Results of the 2025 Annual Meeting of Shareholders;Change of Name to McEwen Inc. Effective July 7, 2025;Meeting Resources Now Available - July 3, 2025
- Linkage Global Inc Announces First Half 2025 Financial Results - July 3, 2025
